The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of alectinib in combination with bevacizumab as first-line treatment in advanced NSCLC with confirmed ALK fusion: ALEK-B trial.
 
Oscar Gerardo Arrieta
Honoraria - AstraZeneca; Boehringer Ingelheim; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb; Lilly; Merck; Roche
Research Funding - AstraZeneca (Inst); BMS (Inst); Merck (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Lilly
 
Luis Antonio Lara Mejía
Speakers' Bureau - Boehringer Ingelheim
Expert Testimony - Boehringer Ingelheim
Travel, Accommodations, Expenses - Boehringer Ingelheim
 
Luis Antonio Cabrera
No Relationships to Disclose
 
Maritza Ramos
No Relationships to Disclose
 
David Jose Heredia
Honoraria - Roche; Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Graciela Cruz-Rico
No Relationships to Disclose
 
Miguel Angel Salinas
No Relationships to Disclose
 
Daniela Cardenas Fernández
No Relationships to Disclose
 
Zyanya Lucía Zatarain-Barron
No Relationships to Disclose
 
Andres Felipe Cardona Zorrilla
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Celldex; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation for Clinical and Applied Cancer Research (FICMAC); Foundation Medicine; Merck Sharp & Dohme; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; Foundation for Clinical and Applied Cancer Research (FICMAC); Foundation Medicine; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Merck Sharp & Dohme; Roche
 
Jordi Remon Masip
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; OSE Immunotherapeutics; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Inivata; OSE Immunotherapeutics; OSE Immunotherapeutics; Roche/Genentech
 
Rafael Rosell
Consulting or Advisory Role - Blueprint Medicines; Merck KGaA